SS
TOVX icon

SBI Securities’s Theriva Biologics TOVX Stock Holding History

SBI Securities’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$90 Buy
358
+227
+173% +$67 ﹤0.01% 3533
2026
Q1 		$26 Buy
131
+72
+122% +$14 ﹤0.01% 3716
2025
Q4 		$12 Hold
59
– – ﹤0.01% 3856
2025
Q3 		$24 Sell
59
-1
-2% – ﹤0.01% 3888
2025
Q2 		$26 Buy
60
+50
+500% +$41 ﹤0.01% 3866
2025
Q1 		$11 Hold
10
– – ﹤0.01% 3959
2024
Q4 		$18 Buy
+10
New +$15 ﹤0.01% 3856

Other funds holding TOVX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

SBI Securities's TOVX Position: Q2 2026 in Review

SBI Securities increased its Theriva Biologics (TOVX) stake by 173% in Q2 2026, buying an estimated $67 and bringing the position to 358 shares worth $90. The position accounts for ﹤0.01% of the portfolio, ranked #3533.

SBI Securities first reported a position in TOVX in Q4 2024 and has held it in 7 quarters since. 26 funds tracked by Wall St. Rank hold TOVX as of Q2 2026.

  • SBI Securities held 358 shares of Theriva Biologics worth $90 as of Q2 2026.
  • SBI Securities bought 227 Theriva Biologics shares in Q2 2026, an estimated $67.
  • Theriva Biologics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3533 holding.
  • SBI Securities first reported a position in Theriva Biologics in Q4 2024 and has held it in 7 quarters since.
  • 26 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.